hrp0089p1-p145 | GH & IGFs P1 | ESPE2018

Response to Growth Hormone in Patients with Isolated Familial Growth Hormone Deficiency due to RNPC3 Mutations

Travieso-Suarez Lourdes , Martos-Moreno Gabriel , Pozo Jesus , Munoz-Calvo Maria , Chowen Julie , Frilander Mikko , Perez-Jurado Luis , Hawkins Federico , Argente Jesus

Background: We recently reported three children with severe isolated growth hormone (GH) deficiency and pituitary hypoplasia due to biallelic mutations in the RNPC3 gene, which codes for a minor spliceosome protein required for U11/U12 small nuclear ribonucleoprotein formation and splicing of U12-type introns. Although it is clear that these patients are GH deficient, the underlying mechanism for this deficit is not totally understood.Objective:...

hrp0089p3-p204 | GH & IGFs P3 | ESPE2018

Children Born Small for Gestational Age Treated with Growth Hormone: Evolutionary Aspects

Vazquez Veronica Maria Padin , Costa David Albino Gomez , Garcia Aida Del Campo , Cordo Lourdes Rey , Martin Jose Luis Chamorro , Lorenzo Jose Ramon Fernandez

Introduction: Short stature is defined as stature less than −2 standars deviations (SD) for a person’s age and sex of the reference population. Short for gestational age children (SGA) represent 20% of all children with short stature. 10% of these can not catch-up and remains their height below −2 SD. Growth hormone (GH) treatment is a recognized therapy for SGA children authorized in Europe at 4 years old. There are studies that support that younger children ...

hrp0089p3-p211 | GH & IGFs P3 | ESPE2018

Study of the Effectiveness of GH in Children Born Small for Gestational Age in an Area of Northwestern Spain and its Associated Factors

Rodriguez Paloma Cabanas , Cordo Lourdes Rey , Fernandez Antonio Bello , Martin Jose Luis Chamorro , Carro Ana Prado , Rego Ruben , Castro-Feijoo Lidia , Dans Alicia Cepedano , Conde Jesus Barreiro

Introduction: Recombinant GH is an effective treatment for short children who are born small for gestational age(SGA). Short children SGA who fail catch-up growth by 4 years of age are candidates for GH treatment, at a dose of 35–70 μg/kg per day. Factors associated with response to GH treatment during the initial 2–3 years of therapy include age and height standard deviation scores at the start of therapy, midparental height, and GH dose. It is important to kno...

hrp0086fc14.4 | Growth : Mechanisms | ESPE2016

Preferential Paternal Transmission of the T Allele for the rs1802710 Polymorphism In Dlk1 Gene as a Pre- and Postnatal Growth Regulator

Prats-Puig Anna , Carreras-Badosa Gemma , Xargay-Torrent Silvia , Petry Clive J , Redondo-Bautista Lara , de Zegher Francis , Bassols Judit , Ibanez Lourdes , Dunger David B , Lopez-Bermejo Abel

Background: DLK1 or PREF1 is an imprinted gene highly expressed from the paternal allele in embryonic tissues and placenta. It has been recently implicated in adipose tissue expansion and diabetes development. The human rs1802710 polymorphism (SNP) in DLK1 gene has been associated with early-onset extreme obesity but its role determining growth is unknown.Objective and hypotheses: To study the preferential paternal transmission...

hrp0086fc14.5 | Growth : Mechanisms | ESPE2016

Preferential Transmission of the Paternal C Allele of the rs9373409 Polymorphism in plagl1 Gene as a Regulator of Fetal Growth and Maternal Metabolism

Prats-Puig Anna , Carreras-Badosa Gemma , Diaz-Roldan Ferran , Petry Clive J , Maldonado-Moreno Clara , de Zegher Francis , Bassols Judit , Ibanez Lourdes , Dunger David B , Lopez-Bermejo Abel

Background: The phenotypic effects of single nucleotide polymorphisms (SNPs) may depend on their parental origin. PLAGL1 is an imprinted gene expressed from the paternal allele in placenta that is associated with fetal growth, transient neonatal diabetes mellitus and postnatal growth disorders. The mechanisms whereby PLAG1 regulates fetal growth are, however, unknown.Objective and hypotheses: To study if the preferential paternal transm...

hrp0086rfc10.2 | Perinatal Endocrinology | ESPE2016

Dysregulation of Placental Mirna in Maternal Obesity is Associated with Pre-and Post-Natal Growth

Bassols Judit , Carreras-Badosa Gemma , Bonmati Alexandra , Ortega Francisco-Jose , Mercader Josep-Maria , Prats-Puig Anna , deZegher Francis , Ibanez Lourdes , Fernandez-Real Jose-Manuel , Lopez-Bermejo Abel

Background: Human placenta exhibits a specific miRNA expression pattern. Some of these miRNAs are dysregulated in pregnancy disorders like preeclampsia and intrauterine growth restriction (IUGR), and are potential biomarkers for these pathologies. No studies have been performed in maternal obesity.Objective and hypotheses: (1) Define the placental miRNA profile in pregnant women with: a) pre-pregnancy (preOB) or gestational obesity (gestOB), b) gestation...

hrp0086rfc10.8 | Perinatal Endocrinology | ESPE2016

Gestational Diabetes is Associated with Changes in Placental Microbiota and Microbiome

Bassols Judit , Serino Matteo , Carreras-Badosa Gemma , Burcelin Remy , Blasco-Baque Vincent , Prats-Puig Anna , de Zegher Francis , Ibanez Lourdes , Fernandez-Real Jose-Manuel , Lopez-Bermejo Abel

Background: The human microbiota has emerged as an unexpected modulator of the immune system. The placenta, long thought to be sterile, harbors a unique microbiome and variations in their composition could be related to prevent pregnancy disorders.Objective and hypotheses: To profile the placental microbiota (microorganisms) and microbiome (collection of microbial genomes in an environment) in women with gestational diabetes (GDM) and study their relatio...

hrp0086p1-p799 | Syndromes: Mechanisms and Management P1 | ESPE2016

NPR2 Gene Mutations Associated with Acromesomelic Dysplasia Maroteaux Type are Mostly Unique to Families

Castro-Feijoo Lidia , Barreiro Jesus , Guillen-Navarro Encarna , Journel Hubert , Wakeling Emma , Jagadeesh Sujatha , LeMerrer Martine , Silva Paula , Cabanas Paloma , Pombo Manuel , Loidi Lourdes

Background: Acromesomelic dysplasia Maroteaux type (AMDM) (OMIM 602875) is a rare autosomal recessive skeletal disorder with an approximate prevalence of 1/1,000,000) and characterized by severe dwarfism accompanied by shortness of distal and middle segments of extremities. Mutations in the NPR2 gene which encodes for the natriuretic peptide receptor B (NPR-B) is the underlying genetic cause of this disorder.Objective and hypotheses: Genetic con...

hrp0082fc8.4 | Fat Metabolism | ESPE2014

CREB-Regulated Transcription Coactivator 3: a New Adipokine Related to Childhood Obesity

Prats-Puig Anna , Soriano-Rodriguez Pilar , Oliveras Gloria , Blancafort Adriana , Diaz-Roldan Ferran , Carreras-Badosa Gemma , de Zegher Francis , Ibanez Lourdes , Bassols Judit , Puig Teresa , Lopez-Bermejo Abel

Background: CREB-regulated transcription coactivator 3 (CRTC3) is found in adipocytes where it may promote obesity through disruption of catecholamine signaling. CRTC3 knockout mice are resistant to diet-induced obesity.Objective and Hypotheses: The goals of the present study were i) to assess whether CRTC3 is a soluble protein secreted by adipose tissue ii) to explore whether CRTC3 is detectable and quantifiable in the circulation, and iii) to ...

hrp0082fc10.2 | Programming & Early Endocrinology | ESPE2014

Stk11 Expression in Adipose Tissue Following Fetal Growth Restriction: Relation to Catch-Up Growth and Visceral Fat Mass

Carreras-Badosa Gemma , Remesar Xavier , Prats-Puig Anna , Platero-Gutierrez Estibaliz , de Zegher Francis , Ibanez Lourdes , Bassols Judit , Lopez-Bermejo Abel

Background: STK11 regulates glucose and lipid metabolism. In adult rats, excessive fat deposition and dysfunctional metabolism are related to low STK11 expression in adipose tissue. It is unknown if low STK11 expression in adipose tissue relates also to catch-up growth and fat deposition after intrauterine growth restriction.Objective and Hypotheses: To assess the expression of STK11 in adipose tissue and its relation ...